TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Scribe Therapeutics and Sanofi Extend In Vivo Collaboration to Include Second Target

Thursday, January 04, 2024

Scribe Therapeutics Inc., a company specializing in genetic medicines harnessing the potential of CRISPR to revolutionize human health, has disclosed that Sanofi (NASDAQ: SNY) has opted for a second target in their ongoing research collaboration to create in vivo CRISPR-based therapeutics. The collaboration is aimed at utilizing CRISPR technology for potentially transformative genetic medicines.

Benjamin Oakes, Ph.D., co-founder and Chief Executive Officer of Scribe, expressed satisfaction with the progress made in developing groundbreaking genetic medicines. The collaboration merges Scribe's CRISPR technologies with Sanofi's expertise in genomic medicine, establishing a solid foundation for pioneering in vivo treatments.

Scribe's inventive CRISPR by Design™ approach, which emphasizes data-driven design and engineering, particularly its X-Editing (XE) technologies, continues to push the boundaries of genetic medicine. The company is set to receive a milestone payment tied to the second target nomination and is eligible for additional development and commercial milestones as the program progresses.

The initial collaboration between Scribe and Sanofi, unveiled in 2022, concentrated on CRISPR-based cell therapies for addressing oncology indications. This was followed by an expansion in 2023 to encompass the development of in vivo medicines for genomic diseases. The collaborative effort underscores their dedication to bringing innovative genetic therapies to patients in need.



patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit